MegaLT injection for faster platelet recovery after cord blood transplant
Part of Blood & lymphatic clinical trials.
This study tests an injection called MegaLT to help your body make platelets (blood cells that help stop bleeding) faster after a cord blood transplant. If you are recovering from a cord blood transplant for a blood cancer, this might help reduce the time you need platelet transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a blood cancer (like leukemia or lymphoma) and are getting a cord blood stem cell transplant.
- You are about 2 weeks (day 14) after your cord blood transplant.
- You are generally able to take care of yourself and are not bedridden (ECOG performance status 2 or better).
- You do not have serious infections, heart/lung/kidney problems, or a history of blood clots.
- You must agree to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection made from umbilical cord blood to raise low platelet counts caused by cancer therapies like chemo, immunotherapy, or radiation. It may help people with mild to moderate low platelets who haven't had recent platelet transfusions or other platelet-raising drugs.
This trial tests a drug called Romiplostim N01 to help platelet levels recover faster in people with blood cancers who have had a cord blood transplant. It may reduce the need for platelet transfusions and lower bleeding risk.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.